RA PHARMACEUTICALS, INC. Clinical Trials
Studies registered on ClinicalTrials.gov (U.S. National Library of Medicine) with the company as lead sponsor or collaborator, newest start first. Values are as registered.
- 2019-09-17: Study NCT04115293; Company role Lead sponsor; Phase Phase 3; Status Completed.
- 2017-07-17: Study NCT03225287; Company role Lead sponsor; Phase Phase 2; Status Terminated.
| Start date | Study | Company role | Phase | Status | Conditions | Enrollment | Completion date |
|---|---|---|---|---|---|---|---|
| 2019-09-17 | NCT04115293 Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia Gravis | Lead sponsor | Phase 3 | Completed Results posted | Myasthenia Gravis, Generalized | 174 | 2021-12-30 |
| 2017-07-17 | NCT03225287 Extension Study of RA101495 for Patients With PNH Who Have Completed a Zilucoplan (RA101495) Clinical Study | Lead sponsor | Phase 2 | Terminated Results posted | Paroxysmal Nocturnal Hemoglobinuria (PNH) | 19 | 2021-10-26 |